We recently published our article 5 Best Cheap AI Medicine Stocks to Buy Now. To read the full article, head on to 10 Best Cheap AI Medicine Stocks to Buy Now. In this piece, we take a closer look at RadNet Inc. (NASDAQ:RDNT) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.
Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.
Interestingly, the term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.
Why Medicine Could Be AI’s Next Major Market
Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.
Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.
These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.
A Low Share Price Does Not Always Mean Cheap
A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.
The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.
Finding the Best AI Medicine Stocks
This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.
The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.
CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.
Our Methodology
For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.
5 Best Cheap AI Medicine Stocks to Buy Now
3. RadNet Inc. (NASDAQ:RDNT)
RadNet, Inc. (NASDAQ: RDNT) takes third place because it combines a large operating medical-imaging business with one of the fastest-growing radiology AI platforms in the public market.
The company operates outpatient diagnostic-imaging centers while developing digital-health products through its DeepHealth subsidiary. This structure gives it a significant real-world advantage. AI tools can be developed and tested within an existing imaging network before being offered to outside hospitals, radiology practices and healthcare systems.
The digital-health portfolio uses artificial intelligence to assist with image interpretation, cancer detection, workflow management and clinical reporting. Its technology addresses a major challenge in healthcare: imaging volumes continue to rise while many markets face shortages of trained radiologists.
Reporting Pro, for example, uses AI to help radiologists produce clinical reports and communicate findings more efficiently. Other applications focus on detecting abnormalities in mammography and additional imaging procedures. These products could improve productivity without requiring AI to replace the physician making the final clinical decision.
Second-quarter 2026 total revenue increased 25% to approximately $622.7 million. Digital Health revenue surged 56.5% to $32.4 million, while annual recurring revenue reached $105.5 million—nearly double its level from a year earlier. The company reported record quarterly revenue and raised its financial guidance.
At approximately $73.71 per share and a market capitalization of roughly $5.8 billion, the stock is not cheap based on current GAAP earnings. The company also carries debt and has pursued acquisitions to support growth.
What makes the shares attractive is the combination of an established healthcare operation and rapidly expanding AI revenue. If the digital-health segment maintains its current momentum, it could eventually command a software-style valuation separate from the traditional imaging-center business.
YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
